Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $41.44 Consensus Target Price from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.44.

A number of research firms recently issued reports on ARWR. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Piper Sandler reduced their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. B. Riley reiterated a “buy” rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th.

Arrowhead Pharmaceuticals Trading Up 1.8 %

NASDAQ:ARWR opened at $17.67 on Friday. Arrowhead Pharmaceuticals has a 12-month low of $16.57 and a 12-month high of $35.80. The firm has a market capitalization of $2.23 billion, a P/E ratio of -3.42 and a beta of 0.95. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The business has a 50 day simple moving average of $19.46 and a 200 day simple moving average of $20.60.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Equities research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the sale, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at $64,230,110.04. The trade was a 3.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kenneth Allen Myszkowski sold 27,167 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the sale, the chief financial officer now directly owns 473,433 shares in the company, valued at $9,388,176.39. This trade represents a 5.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 280,765 shares of company stock valued at $5,227,313. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $38,000. GF Fund Management CO. LTD. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at $49,000. Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the period. Finally, KBC Group NV raised its position in Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.